DUPHALAC (lactulose), hypoammonaemic osmotic laxative

Opinions on drugs - Posted on Jun 27 2018

Reason for request

Renewal of inclusion

Moderate clinical benefit for hepatic encephalopathy and constipation


  • DUPHALAC has been granted a marketing authorisation for hepatic encephalopathy and for the symptomatic treatment of constipation.

  • In cases of constipation, it should only be envisaged after lifestyle and dietary measures have failed and in combination with such measures.

  • In cases of hepatic encephalopathy, it is recommended in cases of minimal or subclinical encephalopathy as a first-line symptomatic treatment in the acute phase, supplementing triggering factor management, and for preventing recurrences, with a non-optimal level of evidence.



Clinical Benefit



Contact Us

Évaluation des médicaments